{"gene":"TOR1A","run_date":"2026-06-10T10:51:55","timeline":{"discoveries":[{"year":1999,"finding":"TOR1A (torsinA) and its homologue TOR1B are located adjacent on chromosome 9q34, each comprising five similar exons spanning ~10 kb. The encoded proteins share functional domains with the AAA/HSP/Clp-ATPase superfamily of chaperone-like proteins, representing a distinct evolutionary branch. A family of at least nine related genes exists across human, mouse, rat, pig, zebrafish, fruitfly, and nematode.","method":"Genomic cloning, sequence analysis, database search, and phylogenetic comparison","journal":"Genomics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct genomic characterization with sequence and domain analysis, single lab but multiple orthogonal methods","pmids":["10644435"],"is_preprint":false},{"year":2007,"finding":"Mutant torsinA (ΔE) interferes with protein processing through the secretory/ER pathway. Primary fibroblasts from DYT1 patients secreted markedly less Gaussia luciferase reporter activity compared with controls, and mouse embryonic fibroblasts lacking torsinA also showed reduced secretion, supporting a role for torsinA as an ER chaperone. TorsinA was found to associate (co-fractionate) with Gluc reporter in the ER lumen.","method":"Gaussia luciferase secretion reporter assay in primary DYT1 patient fibroblasts and torsinA-null MEFs; brefeldin A/nocodazole inhibition; subcellular fractionation; fluorescent protein fusion colocalization","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (reporter assay, pharmacological inhibition, KO MEFs, fractionation), patient cells and KO cells converge on same conclusion","pmids":["17428918"],"is_preprint":false},{"year":2010,"finding":"THAP1 (DYT6 protein), a transcription factor, directly binds the core promoter of TOR1A and represses TOR1A expression. Dystonia-6-associated mutant THAP1 shows decreased repression of TOR1A, indicating transcriptional dysregulation of TOR1A as a disease mechanism.","method":"TOR1A promoter characterization; THAP1 binding to TOR1A promoter demonstrated by reporter assay and ChIP-type analysis; luciferase reporter assay comparing wild-type vs. mutant THAP1","journal":"Annals of neurology","confidence":"High","confidence_rationale":"Tier 2 / Moderate — promoter binding and transcriptional repression shown by multiple functional assays (promoter characterization, reporter assay, mutant comparison), single lab","pmids":["20976771"],"is_preprint":false},{"year":2008,"finding":"The DYT1 ΔE mutation causes mutant torsinA to redistribute from the endoplasmic reticulum to the nuclear envelope. The mutation also triggers formation of abnormal intermolecular disulfide bond-dependent oligomers in torsinA. Wild-type torsinA is degraded primarily through autophagy, while the mutant form additionally requires the proteasome for efficient clearance; disulfide-linked oligomers of mutant torsinA interfere with proteasomal degradation, relying instead on autophagy.","method":"Subcellular localization studies; biochemical analysis of disulfide bonds; pharmacological inhibition of autophagy (rapamycin) and proteasome; pulse-chase degradation assays in transfected cells","journal":"Neuroscience","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple biochemical methods in single lab; cell-based with pharmacological validation","pmids":["18940237"],"is_preprint":false},{"year":2011,"finding":"The DYT1 disease-causing ΔE mutation promotes an abnormal association between torsinA and SUN1, a LINC complex component at the inner nuclear membrane. siRNA depletion of SUN1 (but not other LINC complex proteins) removes torsinA-ΔE from the nuclear envelope. This SUN1-dependent localization requires the torsinA membrane association domain and residue Y147. In contrast, ATP-locked torsinA accumulates at the NE via LAP1, not SUN1, indicating two distinct NE-localized binding interactions.","method":"Co-immunoprecipitation; siRNA knockdown of LINC complex components; subcellular localization by immunofluorescence; site-directed mutagenesis of torsinA","journal":"BMC cell biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal localization/co-IP approach, siRNA knockdown, mutagenesis; single lab","pmids":["21627841"],"is_preprint":false},{"year":2011,"finding":"Conditional knockout of Dyt1 specifically in Purkinje cells recapitulates the dendritic morphology defects (shortened primary dendrites, decreased distal dendritic spines) seen in Dyt1 ΔGAG knock-in mice, demonstrating that the torsinA effect on Purkinje cell morphology is cell-autonomous.","method":"Purkinje cell-specific Cre-mediated conditional knockout; Golgi staining for dendritic morphology quantification; comparison with ΔGAG knock-in mice","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — cell-type-specific KO with defined morphological phenotype, single lab with two complementary mouse models","pmids":["21479250"],"is_preprint":false},{"year":2011,"finding":"Loss of torsinA specifically in the striatum (striatum-specific Dyt1 conditional knockout) is sufficient to produce motor deficits and reduced striatal dopamine receptor 2 (D2R) binding activity, without significant alteration of striatal monoamine contents or nuclear envelope abnormalities in adult neurons.","method":"Striatum-specific Cre-mediated conditional knockout; behavioral motor testing; D2R radioligand binding assay; monoamine HPLC; nuclear envelope electron microscopy","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — cell-type-specific KO with defined behavioral and biochemical phenotypes, single lab","pmids":["21931745"],"is_preprint":false},{"year":2011,"finding":"Loss-of-function of Drosophila dtorsin (the sole TOR1A ortholog) results in severely reduced dopamine levels in larval and adult brains. dtorsin mutants show a strong genetic interaction with Punch (GTP cyclohydrolase/DYT14 ortholog), and biochemical analysis revealed severe reduction in GTP cyclohydrolase protein and activity, establishing that dtorsin acts as a positive regulator of GTP cyclohydrolase and dopamine biosynthesis.","method":"Drosophila null mutant generation; dopamine HPLC measurement; GTP cyclohydrolase activity assay; genetic interaction by double mutant analysis; locomotion rescue by dopamine feeding","journal":"PloS one","confidence":"High","confidence_rationale":"Tier 1 / Strong — ortholog null mutant, in vitro enzymatic assay, genetic epistasis, biochemical rescue; multiple orthogonal methods in single study","pmids":["22022556"],"is_preprint":false},{"year":2007,"finding":"The D216H coding-sequence polymorphism in TOR1A moderates the effects of the DYT1 GAG deletion in cellular models and modifies clinical penetrance. In GAG-deletion carriers, the H allele in trans is highly protective against dystonia manifestation, while the D216 allele in cis with the GAG deletion is associated with disease penetrance.","method":"Population genetic analysis of DYT1 GAG-deletion carriers with/without dystonia; haplotype analysis of three TOR1A SNPs including D216H; cellular models previously established","journal":"American journal of human genetics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic epistasis in human cohort combined with reference to cellular model data; large cohort but primarily genetic rather than direct biochemical","pmids":["17503336"],"is_preprint":false},{"year":2008,"finding":"Novel TOR1A missense mutation p.Arg288Gln causes enlarged perinuclear space in HEK293 cells overexpressing the mutant protein, similar to the common ΔGAG mutation, supporting that Arg288 in subdomain alpha5 is functionally important for torsinA activity at the nuclear envelope.","method":"Overexpression of mutant TOR1A p.Arg288Gln in HEK293 cells; subcellular localization and nuclear envelope morphology by fluorescence/electron microscopy","journal":"Journal of neurology, neurosurgery, and psychiatry","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single overexpression experiment, single lab, morphological readout only","pmids":["18477710"],"is_preprint":false},{"year":2009,"finding":"A novel TOR1A missense mutation F205I (in the AAA-ATPase domain) produces frequent intracellular inclusions when expressed in cells, similar to the ΔGAG mutation, providing functional evidence that this mutation impairs torsinA function.","method":"Expression assay with F205I and ΔGAG TOR1A variants; intracellular inclusion formation scored by microscopy","journal":"Journal of medical genetics","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single overexpression/inclusion assay, single lab, no biochemical mechanism established","pmids":["19955557"],"is_preprint":false},{"year":2014,"finding":"Rare TOR1A variants R288Q and F205I share biochemical and cellular properties with pathogenic torsinAΔE (altered oligomerization, subcellular redistribution toward nuclear envelope, altered degradation via autophagy-lysosome pathway), whereas wild-type torsinA does not display these features. Autophagy-lysosome pathway is the preferred degradation route for both wild-type and most mutant torsinA forms.","method":"Subcellular localization assays; co-immunoprecipitation for oligomerization; autophagy/proteasome pharmacological inhibition; protein stability assays; comparison across multiple variants","journal":"Human mutation","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal biochemical assays across variants in single lab","pmids":["24930953"],"is_preprint":false},{"year":2014,"finding":"TOR1A mutant variants (including ΔGAG) show preferred degradation through the autophagy-lysosome pathway. Blocking autophagy with bafilomycin significantly increases inclusion formation for the E121K variant. The p.A14_P15del mutation affects the proposed oligomerization domain but does not abolish dimerization.","method":"Autophagy inhibition (bafilomycin), protein stability assays, co-immunoprecipitation for dimerization, inclusion body scoring in transfected cells","journal":"Human mutation","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple biochemical methods, single lab","pmids":["24931141"],"is_preprint":false},{"year":2015,"finding":"Gene dosage studies using a conditional knock-in allele demonstrate that ΔE-torsinA is a hypomorphic (loss-of-function) allele with no evidence for gain-of-function toxic properties. The ΔE mutation does not produce dominant negative or toxic gain-of-function effects at the molecular or organismal level.","method":"Conditional Tor1a knock-in allele converted by Cre recombinase; gene dosage study comparing homozygous, heterozygous and wild-type animals at molecular, neuropathological, and behavioral levels","journal":"Human molecular genetics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — conditional allele with systematic dosage study, multiple phenotypic levels assessed, single lab","pmids":["26370418"],"is_preprint":false},{"year":2019,"finding":"D2 receptor protein is reduced in the striatum of juvenile Dyt1 mice through increased lysosomal degradation, controlled by competition between β-arrestin 2 and D2 receptor binding proteins. Striatal RGS9-2 and spinophilin levels are lower in Dyt1 mice. RGS9-2 overexpression rescues both D2 receptor levels and electrophysiological responses in Dyt1 striatal neurons, while RGS9-2 knockout mimics the D2 receptor loss phenotype.","method":"Radioligand binding; Western blot; genetic RGS9-2 knockout and overexpression (viral); electrophysiology in striatal neurons; lysosomal pathway inhibition","journal":"EMBO molecular medicine","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal genetic loss and gain of function with defined biochemical and electrophysiological readouts, mechanistic pathway established, single lab with multiple orthogonal methods","pmids":["30552094"],"is_preprint":false},{"year":2020,"finding":"Lipin phosphatidic acid phosphatase (PAP) enzyme activity is abnormally elevated in human DYT-TOR1A patient iPSC-derived neurons and in four different Tor1a mouse model brains, correlating with Tor1a mutation dosage. Genetic reduction of Lpin1 improves survival of recessive Tor1a disease mice and suppresses neurodegeneration, motor dysfunction, and nuclear membrane pathology, establishing that torsinA loss causes abnormal phosphatidic acid metabolism through excess Lipin activity.","method":"Lipin PAP enzyme activity assay in patient iPSC-derived neurons and mouse brains; genetic interbreeding of Tor1a and Lpin1 knockout mice; behavioral, histopathological, and nuclear membrane analysis","journal":"Brain : a journal of neurology","confidence":"High","confidence_rationale":"Tier 1 / Strong — enzymatic activity assay in human patient cells, multiple mouse models, genetic rescue by Lpin1 KO cross; multiple orthogonal methods across labs","pmids":["32516804"],"is_preprint":false},{"year":2020,"finding":"TorsinB levels bidirectionally regulate DYT1 disease phenotypes. Reducing torsinB levels worsens abnormal movements and neuropathology in DYT1 mouse models in a dose-dependent manner, while torsinB overexpression rescues torsinA loss-of-function-mediated abnormal movements and neurodegeneration, identifying torsinB as a functional paralog capable of compensating for torsinA loss.","method":"Genetic reduction and overexpression of torsinB in DYT1 mouse models; behavioral testing; neuropathological analysis","journal":"eLife","confidence":"High","confidence_rationale":"Tier 2 / Strong — bidirectional genetic manipulation (KO and OE) with defined behavioral and neuropathological readouts in validated disease model","pmids":["32202496"],"is_preprint":false},{"year":2021,"finding":"Human DYT1 patient-specific motor neurons (from iPSCs or direct conversion) show LMNB1 upregulation and abnormal subcellular distribution specifically in cholinergic motor neurons. Ectopic expression of mutant TOR1A or shRNA knockdown of TOR1A in healthy control motor neurons recapitulates LMNB1 dysregulation. Downregulation of LMNB1 ameliorates all major cellular defects in DYT1 motor neurons (reduced neurite length/branching, thickened nuclear lamina, disrupted nuclear morphology, impaired nucleocytoplasmic transport).","method":"iPSC differentiation and direct conversion to cholinergic motor neurons from DYT1 patients; shRNA knockdown; mutant TOR1A overexpression; neurite morphometry; nuclear lamina thickness measurement; nucleocytoplasmic transport assays; Western blot","journal":"The Journal of neuroscience : the official journal of the Society for Neuroscience","confidence":"High","confidence_rationale":"Tier 2 / Strong — human patient-specific neurons, reciprocal gain/loss of function, multiple orthogonal readouts, mechanism-to-rescue validation","pmids":["33468570"],"is_preprint":false},{"year":2018,"finding":"In the Tor1a+/Δgag DYT1 mouse model, long-term potentiation (LTP) appears prematurely in a critical developmental window in striatal spiny neurons while LTD is absent. This is accompanied by increased dendritic spine width, mature mushroom spines, and enhanced AMPA receptor accumulation. BDNF and proBDNF levels are elevated in Tor1a+/Δgag mice, and BDNF antagonism rescues both synaptic plasticity deficits and AMPA currents.","method":"Electrophysiological recording (LTP/LTD) in striatal spiny neurons; dendritic spine morphometry; Western blot for AMPAR and BDNF; pharmacological BDNF antagonism","journal":"eLife","confidence":"High","confidence_rationale":"Tier 2 / Strong — electrophysiology combined with morphological, biochemical, and pharmacological rescue; multiple methods in single study","pmids":["29504938"],"is_preprint":false},{"year":2021,"finding":"Increased vesicular acetylcholine transporter (VAChT) protein levels in the striatum of Tor1a+/- mice lead to elevated basal acetylcholine content and compensatory enhancement of acetylcholinesterase (AChE) activity. Dopamine D2 receptor activation abnormally elevates ACh content (rather than reducing it). Pharmacological blockade of VAChT with vesamicol rescues corticostriatal long-term synaptic plasticity deficits in DYT1 mice.","method":"Western blot for VAChT; acetylcholine content assay; AChE enzymatic activity assay; patch-clamp electrophysiology; pharmacological VAChT inhibition (vesamicol)","journal":"Movement disorders : official journal of the Movement Disorder Society","confidence":"High","confidence_rationale":"Tier 1 / Moderate — enzymatic activity assay, biochemical quantification, electrophysiology with pharmacological rescue; multiple orthogonal methods, single lab","pmids":["34173686"],"is_preprint":false},{"year":2021,"finding":"Conditional expression of Tor1a(ΔE) in dopamine neurons (but not in cholinergic interneurons) reduces striatal dopamine release to ~50% of normal, demonstrating that the dopamine release deficit in DYT1 dystonia is cell-intrinsic to dopaminergic neurons. Other presynaptic mechanisms (electrical excitability, vesicle recycling, Ca2+ signaling, D2 autoreceptor function, GABAB receptor function) are intact in these neurons.","method":"Cell-type-specific conditional expression of Tor1a(ΔE) via Cre drivers; ex vivo fast-scan cyclic voltammetry; in vivo microdialysis; multiple presynaptic mechanism assays","journal":"Neurobiology of disease","confidence":"High","confidence_rationale":"Tier 2 / Strong — cell-type-specific conditional expression with multiple orthogonal electrophysiological and neurochemical assays to define mechanism","pmids":["33894367"],"is_preprint":false},{"year":2022,"finding":"M4 muscarinic receptors on striatal cholinergic interneurons mediate the dopamine-release-enhancing and therapeutic effects of trihexyphenidyl in Tor1a+/ΔE knockin mice. Selective M4 antagonist VU6021625 recapitulates the effect of trihexyphenidyl in restoring striatal dopamine release.","method":"Pharmacological challenges with selective mAChR antagonists; cell-type-specific M4 conditional knockout mice; ex vivo fast-scan cyclic voltammetry","journal":"Neurobiology of disease","confidence":"High","confidence_rationale":"Tier 2 / Strong — cell-type-specific KO combined with pharmacology and voltammetry; mechanistic pathway from mAChR to dopamine release established","pmids":["35314320"],"is_preprint":false},{"year":2023,"finding":"Conditional knockout of Tor1a in the spinal cord and dorsal root ganglia (but not DRG alone) recapitulates early-onset generalized torsion dystonia in mice. Physiological features include spontaneous contractions at rest, excessive/disorganized contractions, co-contractions of antagonist muscles, impaired monosynaptic reflexes, and affected motor neurons in isolated spinal cords, establishing spinal neural circuits as the pathophysiological substrate in this model.","method":"Spinal cord-specific and DRG-specific conditional knockout; behavioral scoring; EMG; electrophysiological recording from isolated spinal cords; monosynaptic reflex arc analysis","journal":"Science translational medicine","confidence":"High","confidence_rationale":"Tier 2 / Strong — cell-type-specific KO with defined behavioral, EMG, and electrophysiological phenotypes; DRG-only KO as negative control strengthens specificity","pmids":["37134150"],"is_preprint":false},{"year":2018,"finding":"Loss of torsinA in the nuclear envelope disrupts LINC complex regulation, causing excess LINC complex accumulation in radial glial cells of Tor1a-/- mouse embryo proliferative zones. This leads to abnormal radial glial polarity and cytoskeletal organization and brain morphogenesis defects in ~30% of Tor1a-/- embryos. Genetic reduction of LINC complexes prevents abnormal brain morphogenesis.","method":"Tor1a-/- embryo brain morphology analysis; immunohistochemistry for LINC complex components and radial glial markers; genetic rescue by LINC complex reduction","journal":"Human molecular genetics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic KO with LINC complex quantification and genetic rescue, single lab","pmids":["29868845"],"is_preprint":false},{"year":2019,"finding":"Trihexyphenidyl increases striatal dopamine release through nicotinic acetylcholine receptor (nAChR)-dependent mechanisms. Dyt1 mice are more sensitive to nAChR antagonism (IC50 ~12 nM vs. ~29 nM in WT) and less sensitive to acetylcholinesterase inhibitors, indicating altered nAChR neurotransmission in DYT1 mice. L-DOPA does not increase dopamine release in Dyt1 mice.","method":"Ex vivo fast-scan cyclic voltammetry; in vivo microdialysis; pharmacological dissection with nAChR antagonists, AChE inhibitors, and L-DOPA","journal":"Neurobiology of disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple pharmacological tools and two complementary neurochemical methods; single lab","pmids":["30707939"],"is_preprint":false},{"year":2007,"finding":"Loss of torsinA function in the cerebral cortex alone (cerebral cortex-specific Dyt1 conditional knockout) is sufficient to produce motor deficits and hyperactivity. Cortex-specific KO mice did not show significant alterations in striatal dopamine and metabolites, unlike Dyt1 ΔGAG knock-in mice.","method":"Cerebral cortex-specific Cre-mediated conditional knockout; behavioral testing (open field, rotarod); monoamine HPLC; barrel cortex anatomy","journal":"Journal of biochemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — cell-type-specific KO with behavioral and neurochemical phenotyping; single lab","pmids":["17956903"],"is_preprint":false},{"year":2019,"finding":"Torsin A loss in D2 receptor-expressing cells (including striatal cholinergic interneurons) leads to significant reductions in: striatal torsinA, acetylcholine metabolic enzymes, TrkA, cholinergic interneuron number, D2R dimers, and tyrosine hydroxylase. This demonstrates that torsinA in D2R-expressing cells is critical for the development/survival of striatal cholinergic interneurons and expression of mature D2R.","method":"D2R-expressing-cell-specific Cre conditional knockout; stereological counting of cholinergic interneurons; Western blot; rotarod and beam-walking tests; monoamine HPLC","journal":"Neurobiology of disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — cell-type-specific KO with multiple biochemical and histological endpoints; single lab","pmids":["31618684"],"is_preprint":false},{"year":2017,"finding":"Novel TOR1A mutation p.Asp194Val (in a patient with early-onset segmental dystonia) induces intracellular inclusion formation in SK-N-AS cells, similar to ΔGAG TOR1A. Co-occurrence with a THAP1 mutation (Leu180Ser) with decreased THAP1 repression of TOR1A suggests a potential additive pathogenic effect.","method":"TOR1A overexpression in SK-N-AS cells; inclusion body scoring; luciferase reporter assay for THAP1 repression of TOR1A promoter","journal":"Movement disorders : official journal of the Movement Disorder Society","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single overexpression assay and luciferase reporter, single patient/lab","pmids":["24862462"],"is_preprint":false},{"year":2017,"finding":"TOR1A variants p.Gly318Ser and p.Glu303del (homozygous) cause redistribution of torsinA from the ER to the nuclear envelope in cell assays, establishing this NE redistribution as a common cellular hallmark of pathogenic TOR1A mutations and linking biallelic mutations to a severe arthrogryposis phenotype.","method":"Cell-based torsinA subcellular localization assay (overexpression); comparison of WT vs. mutant localization","journal":"Brain : a journal of neurology","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single localization assay, single lab","pmids":["29053766"],"is_preprint":false}],"current_model":"TorsinA is an AAA+-family chaperone-like ATPase that normally resides in the ER lumen and nuclear envelope, where it regulates nuclear envelope integrity (via LAP1 and SUN1/LINC complex interactions), protein secretion through the ER, phosphatidic acid metabolism (via Lipin regulation), and dopamine neurotransmission (cell-intrinsically within dopaminergic neurons via an unknown presynaptic mechanism); the disease-causing ΔE mutation renders it hypomorphic, redistributes it to the nuclear envelope via an aberrant SUN1 interaction, elevates LMNB1 in neurons, disrupts nucleocytoplasmic transport, impairs corticostriatal synaptic plasticity through excess VAChT/acetylcholine and altered BDNF-AMPAR signaling, reduces striatal D2R levels through increased lysosomal degradation controlled by RGS9-2/β-arrestin competition, and can be functionally compensated by its paralog torsinB."},"narrative":{"mechanistic_narrative":"TorsinA, encoded by TOR1A, is an AAA+/HSP/Clp-superfamily chaperone-like ATPase that resides in the ER lumen and contiguous nuclear envelope and supports nuclear envelope integrity, ER protein secretion, lipid metabolism, and dopaminergic neurotransmission [PMID:10644435, PMID:17428918]. In the ER it acts as a chaperone facilitating protein processing through the secretory pathway, as DYT1 patient fibroblasts and torsinA-null cells secrete a reporter poorly [PMID:17428918]. At the nuclear envelope torsinA regulates the LINC complex: its loss causes excess LINC accumulation that disrupts radial glial polarity, cytoskeletal organization, and brain morphogenesis, all preventable by genetically reducing LINC complexes [PMID:29868845], and ATP-locked torsinA accumulates at the nuclear envelope via LAP1 [PMID:21627841]. TorsinA loss also drives abnormal phosphatidic acid metabolism through excess Lipin phosphatidic acid phosphatase activity, and reducing Lpin1 rescues neurodegeneration, motor dysfunction, and nuclear membrane pathology in disease mice [PMID:32516804]. The dystonia-causing in-frame GAG (ΔE) deletion is a hypomorphic loss-of-function allele rather than a toxic gain-of-function [PMID:26370418]; mutant torsinA forms aberrant disulfide-linked oligomers, redistributes from the ER to the nuclear envelope via an abnormal SUN1 interaction, and is cleared preferentially through the autophagy-lysosome pathway [PMID:18940237, PMID:21627841, PMID:24930953]. This redistribution and altered degradation is a shared cellular hallmark of pathogenic TOR1A variants [PMID:24930953, PMID:29053766]. The functional paralog torsinB compensates bidirectionally for torsinA loss [PMID:32202496], and TOR1A expression is transcriptionally repressed by the dystonia-6 protein THAP1 [PMID:20976771]. Downstream, torsinA dysfunction within dopaminergic neurons cell-intrinsically reduces striatal dopamine release [PMID:33894367], lowers striatal D2 receptor levels via increased lysosomal degradation governed by RGS9-2/β-arrestin competition [PMID:30552094], and disrupts corticostriatal synaptic plasticity through excess VAChT/acetylcholine and altered BDNF–AMPAR signaling [PMID:29504938, PMID:34173686]; in human patient motor neurons, mutant torsinA upregulates LMNB1 and impairs nucleocytoplasmic transport, with LMNB1 reduction reversing these defects [PMID:33468570]. Conditional knockouts establish that spinal/DRG circuits are a pathophysiological substrate for the dystonia phenotype [PMID:37134150]. TOR1A mutations cause early-onset torsion dystonia (DYT1) and, biallelically, a severe arthrogryposis phenotype [PMID:29053766].","teleology":[{"year":1999,"claim":"Establishing TOR1A as an AAA+/HSP/Clp-family chaperone-like ATPase defined the molecular class through which all downstream functions could be interpreted.","evidence":"Genomic cloning, sequence and domain analysis, and phylogenetic comparison across species","pmids":["10644435"],"confidence":"Medium","gaps":["No direct ATPase activity or substrate demonstrated","Subcellular localization not yet established"]},{"year":2007,"claim":"Demonstrating impaired secretion in patient and null cells assigned torsinA a concrete ER chaperone role in the secretory pathway.","evidence":"Gaussia luciferase secretion reporter in DYT1 fibroblasts and torsinA-null MEFs with pharmacological inhibition and fractionation","pmids":["17428918"],"confidence":"High","gaps":["Specific secretory client substrates not identified","Link between secretion defect and neuronal phenotype unresolved"]},{"year":2007,"claim":"Identification of the D216H polymorphism as a penetrance modifier showed that torsinA dosage/activity, not the mutation alone, governs disease manifestation.","evidence":"Population genetics and haplotype analysis of GAG-deletion carriers with cellular model reference","pmids":["17503336"],"confidence":"Medium","gaps":["Biochemical basis of D216H protection not fully defined","Cell-type context of modifier effect unknown"]},{"year":2008,"claim":"Showing that the ΔE mutation redistributes torsinA to the nuclear envelope and shifts its degradation defined the core cellular pathology of mutant protein.","evidence":"Subcellular localization, disulfide-bond biochemistry, and pharmacological autophagy/proteasome inhibition with pulse-chase in transfected cells","pmids":["18940237"],"confidence":"Medium","gaps":["Functional consequence of NE redistribution not established here","Driver of NE retention unknown at this stage"]},{"year":2010,"claim":"Identifying THAP1 as a direct transcriptional repressor of TOR1A connected two genetic dystonia loci into a shared regulatory pathway.","evidence":"Promoter characterization, ChIP-type binding, and reporter assays comparing wild-type vs mutant THAP1","pmids":["20976771"],"confidence":"High","gaps":["In vivo relevance of TOR1A transcriptional dysregulation to dystonia not shown","Other THAP1 target genes not delineated"]},{"year":2011,"claim":"Defining SUN1 as the driver of mutant torsinA NE accumulation, distinct from LAP1-mediated ATP-locked accumulation, explained the abnormal localization mechanism.","evidence":"Co-immunoprecipitation, LINC-component siRNA depletion, and site-directed mutagenesis with immunofluorescence","pmids":["21627841"],"confidence":"Medium","gaps":["Functional consequence of aberrant SUN1 binding unresolved","Single-lab interaction data"]},{"year":2011,"claim":"Cell-type-specific knockouts dissected which neural populations require torsinA, mapping Purkinje cell morphology, striatal motor/D2R, and cortical motor functions to distinct circuits.","evidence":"Purkinje-, striatum-, and cortex-specific conditional Dyt1 knockouts with morphology, behavior, D2R binding, and HPLC","pmids":["21479250","21931745","17956903"],"confidence":"Medium","gaps":["Molecular mechanism linking torsinA loss to each phenotype not resolved","Cross-circuit interactions not addressed"]},{"year":2011,"claim":"The Drosophila ortholog established torsinA as a positive regulator of GTP cyclohydrolase and dopamine biosynthesis, providing a biosynthetic link to dopaminergic deficits.","evidence":"dtorsin null mutants with dopamine HPLC, GTP cyclohydrolase activity assay, genetic interaction with Punch, and dopamine-feeding rescue","pmids":["22022556"],"confidence":"High","gaps":["Direct biochemical mechanism of GTP cyclohydrolase regulation unknown","Conservation of this pathway in mammalian dopaminergic neurons not confirmed"]},{"year":2014,"claim":"Comparative biochemistry of multiple rare variants established NE redistribution, altered oligomerization, and autophagy-lysosome degradation as common signatures of pathogenic torsinA.","evidence":"Subcellular localization, co-IP oligomerization, autophagy/proteasome inhibition, and stability assays across variants","pmids":["24930953","24931141"],"confidence":"Medium","gaps":["Oligomerization domain structure unresolved","Quantitative relationship between degradation route and dysfunction unclear"]},{"year":2015,"claim":"Gene-dosage studies showed ΔE-torsinA is hypomorphic with no toxic gain-of-function, reorienting the disease model toward loss of function.","evidence":"Cre-convertible conditional knock-in allele with homozygous/heterozygous/WT comparison at molecular, neuropathological, and behavioral levels","pmids":["26370418"],"confidence":"Medium","gaps":["Why heterozygous loss suffices for human dystonia not explained","Threshold of activity loss needed for phenotype undefined"]},{"year":2018,"claim":"Linking torsinA loss to LINC complex over-accumulation defined a concrete nuclear envelope mechanism for developmental brain pathology.","evidence":"Tor1a-/- embryo morphology, LINC and radial glial immunohistochemistry, and genetic rescue by LINC complex reduction","pmids":["29868845"],"confidence":"Medium","gaps":["Mechanism by which torsinA limits LINC accumulation not defined","Relevance to adult dystonia circuits unclear"]},{"year":2018,"claim":"Identifying premature LTP, absent LTD, and BDNF-dependent AMPAR changes linked torsinA loss to a developmental synaptic plasticity defect.","evidence":"Striatal LTP/LTD electrophysiology, spine morphometry, AMPAR/BDNF Western blot, and pharmacological BDNF antagonism in Tor1a+/Δgag mice","pmids":["29504938"],"confidence":"High","gaps":["Mechanism linking torsinA to BDNF elevation unknown","Causal sequence between plasticity and motor signs unresolved"]},{"year":2019,"claim":"Defining RGS9-2/β-arrestin-controlled lysosomal degradation of D2R, and the cholinergic dependence of torsinA, mechanistically linked torsinA loss to striatal dopamine/acetylcholine imbalance.","evidence":"Reciprocal RGS9-2 KO/overexpression, radioligand binding, electrophysiology, lysosomal inhibition, and D2R-cell-specific conditional KO","pmids":["30552094","31618684"],"confidence":"High","gaps":["How torsinA loss lowers RGS9-2/spinophilin not defined","Connection between D2R reduction and motor output indirect"]},{"year":2019,"claim":"Pharmacological dissection showed trihexyphenidyl restores striatal dopamine release via altered nAChR neurotransmission, framing anticholinergic therapy mechanistically.","evidence":"Fast-scan cyclic voltammetry and microdialysis with nAChR antagonists, AChE inhibitors, and L-DOPA in Dyt1 mice","pmids":["30707939"],"confidence":"Medium","gaps":["Molecular basis of altered nAChR sensitivity unknown","L-DOPA insensitivity mechanism unexplained"]},{"year":2020,"claim":"Establishing torsinB as a dose-dependent functional paralog and Lipin/phosphatidic acid metabolism as a torsinA-controlled pathway identified two distinct rescue-capable mechanisms.","evidence":"Bidirectional torsinB manipulation in DYT1 mice; Lipin PAP activity assays in patient iPSC neurons and mouse brains with Lpin1 KO genetic rescue","pmids":["32202496","32516804"],"confidence":"High","gaps":["Biochemical mechanism by which torsinA restrains Lipin activity unknown","How torsinB substitutes for torsinA molecularly undefined"]},{"year":2021,"claim":"Human patient motor neurons localized the disease mechanism to LMNB1 upregulation and impaired nucleocytoplasmic transport, with LMNB1 reduction reversing defects.","evidence":"iPSC and direct-conversion cholinergic motor neurons, reciprocal mutant TOR1A overexpression and shRNA knockdown, morphometry, nuclear lamina measurement, and transport assays","pmids":["33468570"],"confidence":"High","gaps":["Mechanistic link between torsinA loss and LMNB1 upregulation unresolved","Cell-type specificity of LMNB1 dysregulation not fully explained"]},{"year":2021,"claim":"Cell-intrinsic conditional expression studies and VAChT findings pinpointed the dopamine-release deficit to dopaminergic neurons and the plasticity deficit to excess vesicular acetylcholine.","evidence":"Cell-type-specific Tor1a(ΔE) expression with voltammetry/microdialysis; VAChT Western blot, ACh and AChE assays, and vesamicol rescue","pmids":["33894367","34173686"],"confidence":"High","gaps":["Presynaptic molecular target of torsinA in dopamine neurons unidentified","Mechanism elevating VAChT unknown"]},{"year":2022,"claim":"Defining M4 muscarinic receptors on cholinergic interneurons as the mediator of anticholinergic dopamine-release enhancement refined the circuit pharmacology of therapy.","evidence":"Selective mAChR antagonists, M4 cell-type-specific conditional knockout, and fast-scan cyclic voltammetry","pmids":["35314320"],"confidence":"High","gaps":["Upstream link from torsinA loss to M4 signaling not established","Generalizability to human therapy untested in this model"]},{"year":2023,"claim":"Spinal cord/DRG conditional knockout identified spinal neural circuits as a sufficient pathophysiological substrate for generalized dystonia.","evidence":"Spinal- and DRG-specific conditional knockouts with behavior, EMG, isolated spinal cord recording, and monosynaptic reflex analysis","pmids":["37134150"],"confidence":"High","gaps":["Molecular mechanism within spinal neurons undefined","Integration of spinal substrate with striatal circuit findings unresolved"]},{"year":null,"claim":"How torsinA's ER/NE chaperone-ATPase activity mechanistically converges on its diverse downstream effects (LINC, Lipin, LMNB1, dopamine release, cholinergic signaling) remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No defined enzymatic substrate connecting torsinA ATPase activity to downstream phenotypes","No structural model of the relevant torsinA complexes in the corpus","Mechanism translating molecular dysfunction into circuit-level dystonia not unified"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140657","term_label":"ATP-dependent activity","supporting_discovery_ids":[0]},{"term_id":"GO:0044183","term_label":"protein folding chaperone","supporting_discovery_ids":[0,1]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[7,15]}],"localization":[{"term_id":"GO:0005783","term_label":"endoplasmic reticulum","supporting_discovery_ids":[1,3]},{"term_id":"GO:0005635","term_label":"nuclear envelope","supporting_discovery_ids":[3,4,23]}],"pathway":[{"term_id":"R-HSA-392499","term_label":"Metabolism of proteins","supporting_discovery_ids":[1,3,11]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[13,17,22]},{"term_id":"R-HSA-112316","term_label":"Neuronal System","supporting_discovery_ids":[14,18,20]}],"complexes":["LINC complex"],"partners":["SUN1","LAP1","THAP1","LMNB1","TOR1B"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"O14656","full_name":"Torsin-1A","aliases":["Dystonia 1 protein","Torsin ATPase-1A","Torsin family 1 member A"],"length_aa":332,"mass_kda":37.8,"function":"Protein with chaperone functions important for the control of protein folding, processing, stability and localization as well as for the reduction of misfolded protein aggregates. Involved in the regulation of synaptic vesicle recycling, controls STON2 protein stability in collaboration with the COP9 signalosome complex (CSN). In the nucleus, may link the cytoskeleton with the nuclear envelope, this mechanism seems to be crucial for the control of nuclear polarity, cell movement and, specifically in neurons, nuclear envelope integrity. Participates in the cellular trafficking and may regulate the subcellular location of multipass membrane proteins such as the dopamine transporter SLC6A3, leading to the modulation of dopamine neurotransmission. In the endoplasmic reticulum, plays a role in the quality control of protein folding by increasing clearance of misfolded proteins such as SGCE variants or holding them in an intermediate state for proper refolding. May have a redundant function with TOR1B in non-neural tissues","subcellular_location":"Endoplasmic reticulum lumen; Nucleus membrane; Cell projection, growth cone; Cytoplasmic vesicle membrane; Cytoplasmic vesicle, secretory vesicle; Cytoplasmic vesicle, secretory vesicle, synaptic vesicle; Cytoplasm, cytoskeleton","url":"https://www.uniprot.org/uniprotkb/O14656/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/TOR1A","classification":"Not Classified","n_dependent_lines":4,"n_total_lines":1208,"dependency_fraction":0.0033112582781456954},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[{"gene":"BTF3","stoichiometry":0.2},{"gene":"CANX","stoichiometry":0.2},{"gene":"RER1","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/search/TOR1A","total_profiled":1310},"omim":[{"mim_id":"618947","title":"ARTHROGRYPOSIS MULTIPLEX CONGENITA 5; AMC5","url":"https://www.omim.org/entry/618947"},{"mim_id":"617468","title":"ARTHROGRYPOSIS MULTIPLEX CONGENITA 1, NEUROGENIC, WITH MYELIN DEFECT; AMC1","url":"https://www.omim.org/entry/617468"},{"mim_id":"617284","title":"DYSTONIA 28, CHILDHOOD-ONSET; DYT28","url":"https://www.omim.org/entry/617284"},{"mim_id":"614513","title":"TORSIN 1A-INTERACTING PROTEIN 2; TOR1AIP2","url":"https://www.omim.org/entry/614513"},{"mim_id":"614512","title":"TORSIN 1A-INTERACTING PROTEIN 1; TOR1AIP1","url":"https://www.omim.org/entry/614512"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Nuclear membrane","reliability":"Supported"},{"location":"Vesicles","reliability":"Supported"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/TOR1A"},"hgnc":{"alias_symbol":["DQ2"],"prev_symbol":["DYT1"]},"alphafold":{"accession":"O14656","domains":[{"cath_id":"3.40.50.300","chopping":"59-270","consensus_level":"high","plddt":90.1443,"start":59,"end":270},{"cath_id":"-","chopping":"275-331","consensus_level":"high","plddt":91.3433,"start":275,"end":331}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/O14656","model_url":"https://alphafold.ebi.ac.uk/files/AF-O14656-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-O14656-F1-predicted_aligned_error_v6.png","plddt_mean":85.38},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=TOR1A","jax_strain_url":"https://www.jax.org/strain/search?query=TOR1A"},"sequence":{"accession":"O14656","fasta_url":"https://rest.uniprot.org/uniprotkb/O14656.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/O14656/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/O14656"}},"corpus_meta":[{"pmid":"9749595","id":"PMC_9749595","title":"Functional brain networks in DYT1 dystonia.","date":"1998","source":"Annals of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/9749595","citation_count":244,"is_preprint":false},{"pmid":"16242683","id":"PMC_16242683","title":"Generation and characterization of Dyt1 DeltaGAG knock-in mouse as a model for early-onset dystonia.","date":"2005","source":"Experimental neurology","url":"https://pubmed.ncbi.nlm.nih.gov/16242683","citation_count":170,"is_preprint":false},{"pmid":"16878175","id":"PMC_16878175","title":"HLA-DQ2 and -DQ8 signatures of gluten T cell epitopes in celiac disease.","date":"2006","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/16878175","citation_count":158,"is_preprint":false},{"pmid":"16527694","id":"PMC_16527694","title":"Human leukocyte antigen-DQ2 homozygosity and the development of refractory celiac disease and enteropathy-associated T-cell lymphoma.","date":"2006","source":"Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association","url":"https://pubmed.ncbi.nlm.nih.gov/16527694","citation_count":155,"is_preprint":false},{"pmid":"11523564","id":"PMC_11523564","title":"Novel mutation in the TOR1A (DYT1) gene in atypical early onset dystonia and polymorphisms in dystonia and early onset parkinsonism.","date":"2001","source":"Neurogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/11523564","citation_count":130,"is_preprint":false},{"pmid":"1347197","id":"PMC_1347197","title":"Strong allelic association between the torsion dystonia gene (DYT1) andloci on chromosome 9q34 in Ashkenazi Jews.","date":"1992","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/1347197","citation_count":123,"is_preprint":false},{"pmid":"12821514","id":"PMC_12821514","title":"Different patterns of electrophysiological deficits in manifesting and non-manifesting carriers of the DYT1 gene mutation.","date":"2003","source":"Brain : a journal of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/12821514","citation_count":122,"is_preprint":false},{"pmid":"10644435","id":"PMC_10644435","title":"The TOR1A (DYT1) gene family and its role in early onset torsion dystonia.","date":"1999","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/10644435","citation_count":120,"is_preprint":false},{"pmid":"17503336","id":"PMC_17503336","title":"Intragenic Cis and Trans modification of genetic susceptibility in DYT1 torsion dystonia.","date":"2007","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/17503336","citation_count":110,"is_preprint":false},{"pmid":"17428918","id":"PMC_17428918","title":"Mutant torsinA interferes with protein processing through the secretory pathway in DYT1 dystonia cells.","date":"2007","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/17428918","citation_count":107,"is_preprint":false},{"pmid":"19718029","id":"PMC_19718029","title":"Differences in the risk of celiac disease associated with HLA-DQ2.5 or HLA-DQ2.2 are related to sustained gluten antigen presentation.","date":"2009","source":"Nature immunology","url":"https://pubmed.ncbi.nlm.nih.gov/19718029","citation_count":107,"is_preprint":false},{"pmid":"15455404","id":"PMC_15455404","title":"Brainstem pathology in DYT1 primary torsion dystonia.","date":"2004","source":"Annals of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/15455404","citation_count":102,"is_preprint":false},{"pmid":"21464304","id":"PMC_21464304","title":"Cerebellothalamocortical pathway abnormalities in torsinA DYT1 knock-in mice.","date":"2011","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/21464304","citation_count":101,"is_preprint":false},{"pmid":"9585364","id":"PMC_9585364","title":"Expression of the early-onset torsion dystonia gene (DYT1) in human brain.","date":"1998","source":"Annals of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/9585364","citation_count":89,"is_preprint":false},{"pmid":"27113773","id":"PMC_27113773","title":"Feedback Regulation of DYT1 by Interactions with Downstream bHLH Factors Promotes DYT1 Nuclear Localization and Anther Development.","date":"2016","source":"The Plant cell","url":"https://pubmed.ncbi.nlm.nih.gov/27113773","citation_count":88,"is_preprint":false},{"pmid":"18299128","id":"PMC_18299128","title":"Abnormal motor function and dopamine neurotransmission in DYT1 DeltaGAG transgenic mice.","date":"2008","source":"Experimental neurology","url":"https://pubmed.ncbi.nlm.nih.gov/18299128","citation_count":80,"is_preprint":false},{"pmid":"20227500","id":"PMC_20227500","title":"Dopamine D2 receptor dysfunction is rescued by adenosine A2A receptor antagonism in a model of DYT1 dystonia.","date":"2010","source":"Neurobiology of disease","url":"https://pubmed.ncbi.nlm.nih.gov/20227500","citation_count":79,"is_preprint":false},{"pmid":"25502872","id":"PMC_25502872","title":"Different binding motifs of the celiac disease-associated HLA molecules DQ2.5, DQ2.2, and DQ7.5 revealed by relative quantitative proteomics of endogenous peptide repertoires.","date":"2014","source":"Immunogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/25502872","citation_count":76,"is_preprint":false},{"pmid":"12783425","id":"PMC_12783425","title":"Toward therapy for DYT1 dystonia: allele-specific silencing of mutant TorsinA.","date":"2003","source":"Annals of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/12783425","citation_count":75,"is_preprint":false},{"pmid":"20976771","id":"PMC_20976771","title":"The dystonia gene DYT1 is repressed by the transcription factor THAP1 (DYT6).","date":"2010","source":"Annals of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/20976771","citation_count":75,"is_preprint":false},{"pmid":"20207699","id":"PMC_20207699","title":"Increased sensorimotor network activity in DYT1 dystonia: a functional imaging study.","date":"2010","source":"Brain : a journal of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/20207699","citation_count":73,"is_preprint":false},{"pmid":"21479250","id":"PMC_21479250","title":"Altered dendritic morphology of Purkinje cells in Dyt1 ΔGAG knock-in and purkinje cell-specific Dyt1 conditional knockout mice.","date":"2011","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/21479250","citation_count":70,"is_preprint":false},{"pmid":"22362761","id":"PMC_22362761","title":"Structural and functional studies of trans-encoded HLA-DQ2.3 (DQA1*03:01/DQB1*02:01) protein molecule.","date":"2012","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/22362761","citation_count":65,"is_preprint":false},{"pmid":"17681795","id":"PMC_17681795","title":"Cyclic and dimeric gluten peptide analogues inhibiting DQ2-mediated antigen presentation in celiac disease.","date":"2007","source":"Bioorganic & medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/17681795","citation_count":64,"is_preprint":false},{"pmid":"29504938","id":"PMC_29504938","title":"Early structural and functional plasticity alterations in a susceptibility period of DYT1 dystonia mouse striatum.","date":"2018","source":"eLife","url":"https://pubmed.ncbi.nlm.nih.gov/29504938","citation_count":64,"is_preprint":false},{"pmid":"21931745","id":"PMC_21931745","title":"Motor deficits and decreased striatal dopamine receptor 2 binding activity in the striatum-specific Dyt1 conditional knockout mice.","date":"2011","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/21931745","citation_count":62,"is_preprint":false},{"pmid":"17956903","id":"PMC_17956903","title":"Motor deficits and hyperactivity in cerebral cortex-specific Dyt1 conditional knockout mice.","date":"2007","source":"Journal of biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/17956903","citation_count":62,"is_preprint":false},{"pmid":"18477710","id":"PMC_18477710","title":"Novel TOR1A mutation p.Arg288Gln in early-onset dystonia (DYT1).","date":"2008","source":"Journal of neurology, neurosurgery, and psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/18477710","citation_count":57,"is_preprint":false},{"pmid":"14872019","id":"PMC_14872019","title":"Mutations in DYT1: extension of the phenotypic and mutational spectrum.","date":"2004","source":"Neurology","url":"https://pubmed.ncbi.nlm.nih.gov/14872019","citation_count":55,"is_preprint":false},{"pmid":"24192268","id":"PMC_24192268","title":"Ex-vivo whole blood secretion of interferon (IFN)-γ and IFN-γ-inducible protein-10 measured by enzyme-linked immunosorbent assay are as sensitive as IFN-γ enzyme-linked immunospot for the detection of gluten-reactive T cells in human leucocyte antigen (HLA)-DQ2·5(+) -associated coeliac disease.","date":"2014","source":"Clinical and experimental immunology","url":"https://pubmed.ncbi.nlm.nih.gov/24192268","citation_count":55,"is_preprint":false},{"pmid":"18513716","id":"PMC_18513716","title":"Commentary: Dopaminergic dysfunction in DYT1 dystonia.","date":"2008","source":"Experimental neurology","url":"https://pubmed.ncbi.nlm.nih.gov/18513716","citation_count":55,"is_preprint":false},{"pmid":"22722545","id":"PMC_22722545","title":"Novel 9q34.11 gene deletions encompassing combinations of four Mendelian disease genes: STXBP1, SPTAN1, ENG, and TOR1A.","date":"2012","source":"Genetics in medicine : official journal of the American College of Medical Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/22722545","citation_count":53,"is_preprint":false},{"pmid":"12975293","id":"PMC_12975293","title":"Frequency and phenotypic variability of the GAG deletion of the DYT1 gene in an unselected group of patients with dystonia.","date":"2003","source":"Archives of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/12975293","citation_count":53,"is_preprint":false},{"pmid":"18832702","id":"PMC_18832702","title":"Complexes of two cohorts of CLIP peptides and HLA-DQ2 of the autoimmune DR3-DQ2 haplotype are poor substrates for HLA-DM.","date":"2008","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/18832702","citation_count":52,"is_preprint":false},{"pmid":"19955557","id":"PMC_19955557","title":"Functional evidence implicating a novel TOR1A mutation in idiopathic, late-onset focal dystonia.","date":"2009","source":"Journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/19955557","citation_count":51,"is_preprint":false},{"pmid":"31974305","id":"PMC_31974305","title":"A molecular basis for the T cell response in HLA-DQ2.2 mediated celiac disease.","date":"2020","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/31974305","citation_count":50,"is_preprint":false},{"pmid":"22393392","id":"PMC_22393392","title":"Genetic background modulates the phenotype of a mouse model of DYT1 dystonia.","date":"2012","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/22393392","citation_count":46,"is_preprint":false},{"pmid":"30552094","id":"PMC_30552094","title":"RGS9-2 rescues dopamine D2 receptor levels and signaling in DYT1 dystonia mouse models.","date":"2019","source":"EMBO molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/30552094","citation_count":44,"is_preprint":false},{"pmid":"18940237","id":"PMC_18940237","title":"Consequences of the DYT1 mutation on torsinA oligomerization and degradation.","date":"2008","source":"Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/18940237","citation_count":39,"is_preprint":false},{"pmid":"26838051","id":"PMC_26838051","title":"TCR sequencing of single cells reactive to DQ2.5-glia-α2 and DQ2.5-glia-ω2 reveals clonal expansion and epitope-specific V-gene usage.","date":"2016","source":"Mucosal immunology","url":"https://pubmed.ncbi.nlm.nih.gov/26838051","citation_count":39,"is_preprint":false},{"pmid":"33468570","id":"PMC_33468570","title":"Disease Modeling with Human Neurons Reveals LMNB1 Dysregulation Underlying DYT1 Dystonia.","date":"2021","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/33468570","citation_count":39,"is_preprint":false},{"pmid":"10714658","id":"PMC_10714658","title":"Frequency of the DYT1 mutation in primary torsion dystonia without family history.","date":"2000","source":"Archives of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/10714658","citation_count":38,"is_preprint":false},{"pmid":"30455354","id":"PMC_30455354","title":"Discriminative T-cell receptor recognition of highly homologous HLA-DQ2-bound gluten epitopes.","date":"2018","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/30455354","citation_count":35,"is_preprint":false},{"pmid":"21627841","id":"PMC_21627841","title":"The nuclear envelope localization of DYT1 dystonia torsinA-ΔE requires the SUN1 LINC complex component.","date":"2011","source":"BMC cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/21627841","citation_count":35,"is_preprint":false},{"pmid":"17013905","id":"PMC_17013905","title":"Neuropsychological profile of DYT1 dystonia.","date":"2006","source":"Movement disorders : official journal of the Movement Disorder Society","url":"https://pubmed.ncbi.nlm.nih.gov/17013905","citation_count":33,"is_preprint":false},{"pmid":"29053766","id":"PMC_29053766","title":"TOR1A variants cause a severe arthrogryposis with developmental delay, strabismus and tremor.","date":"2017","source":"Brain : a journal of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/29053766","citation_count":32,"is_preprint":false},{"pmid":"24931141","id":"PMC_24931141","title":"Unraveling cellular phenotypes of novel TorsinA/TOR1A mutations.","date":"2014","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/24931141","citation_count":30,"is_preprint":false},{"pmid":"24500857","id":"PMC_24500857","title":"Heterogeneity in primary dystonia: lessons from THAP1, GNAL, and TOR1A in Amish-Mennonites.","date":"2014","source":"Movement disorders : official journal of the Movement Disorder Society","url":"https://pubmed.ncbi.nlm.nih.gov/24500857","citation_count":30,"is_preprint":false},{"pmid":"26370418","id":"PMC_26370418","title":"A novel conditional knock-in approach defines molecular and circuit effects of the DYT1 dystonia mutation.","date":"2015","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/26370418","citation_count":30,"is_preprint":false},{"pmid":"20825472","id":"PMC_20825472","title":"Clinical and genetic evaluation of DYT1 and DYT6 primary dystonia in China.","date":"2010","source":"European journal of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/20825472","citation_count":30,"is_preprint":false},{"pmid":"24951854","id":"PMC_24951854","title":"Negative allosteric modulation of mGlu5 receptor rescues striatal D2 dopamine receptor dysfunction in rodent models of DYT1 dystonia.","date":"2014","source":"Neuropharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/24951854","citation_count":30,"is_preprint":false},{"pmid":"27716431","id":"PMC_27716431","title":"Tor1a+/- mice develop dystonia-like movements via a striatal dopaminergic dysregulation triggered by peripheral nerve injury.","date":"2016","source":"Acta neuropathologica communications","url":"https://pubmed.ncbi.nlm.nih.gov/27716431","citation_count":29,"is_preprint":false},{"pmid":"30707939","id":"PMC_30707939","title":"Trihexyphenidyl rescues the deficit in dopamine neurotransmission in a mouse model of DYT1 dystonia.","date":"2019","source":"Neurobiology of disease","url":"https://pubmed.ncbi.nlm.nih.gov/30707939","citation_count":29,"is_preprint":false},{"pmid":"19284587","id":"PMC_19284587","title":"High-throughput mutational analysis of TOR1A in primary dystonia.","date":"2009","source":"BMC medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/19284587","citation_count":28,"is_preprint":false},{"pmid":"22391119","id":"PMC_22391119","title":"Improved motor performance in Dyt1 ΔGAG heterozygous knock-in mice by cerebellar Purkinje-cell specific Dyt1 conditional knocking-out.","date":"2012","source":"Behavioural brain research","url":"https://pubmed.ncbi.nlm.nih.gov/22391119","citation_count":28,"is_preprint":false},{"pmid":"19202559","id":"PMC_19202559","title":"The TOR1A polymorphism rs1182 and the risk of spread in primary blepharospasm.","date":"2009","source":"Movement disorders : official journal of the Movement Disorder Society","url":"https://pubmed.ncbi.nlm.nih.gov/19202559","citation_count":28,"is_preprint":false},{"pmid":"21241782","id":"PMC_21241782","title":"The DYT1 carrier state increases energy demand in the olivocerebellar network.","date":"2011","source":"Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/21241782","citation_count":28,"is_preprint":false},{"pmid":"28081261","id":"PMC_28081261","title":"The Role of TOR1A Polymorphisms in Dystonia: A Systematic Review and Meta-Analysis.","date":"2017","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/28081261","citation_count":27,"is_preprint":false},{"pmid":"12439617","id":"PMC_12439617","title":"TNF alpha and LT alpha gene polymorphisms as additional markers of celiac disease susceptibility in a DQ2-positive population.","date":"2002","source":"Immunogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/12439617","citation_count":27,"is_preprint":false},{"pmid":"37134150","id":"PMC_37134150","title":"Pathophysiology of Dyt1-Tor1a dystonia in mice is mediated by spinal neural circuit dysfunction.","date":"2023","source":"Science translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/37134150","citation_count":26,"is_preprint":false},{"pmid":"16911351","id":"PMC_16911351","title":"Clinical characterization and evaluation of DYT1 gene in Indian primary dystonia patients.","date":"2006","source":"Acta neurologica Scandinavica","url":"https://pubmed.ncbi.nlm.nih.gov/16911351","citation_count":26,"is_preprint":false},{"pmid":"20547426","id":"PMC_20547426","title":"HLA-DQ2+ individuals are susceptible to Hu-Ab associated paraneoplastic neurological syndromes.","date":"2010","source":"Journal of neuroimmunology","url":"https://pubmed.ncbi.nlm.nih.gov/20547426","citation_count":26,"is_preprint":false},{"pmid":"33638639","id":"PMC_33638639","title":"Striatal and cerebellar vesicular acetylcholine transporter expression is disrupted in human DYT1 dystonia.","date":"2021","source":"Brain : a journal of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/33638639","citation_count":24,"is_preprint":false},{"pmid":"31618684","id":"PMC_31618684","title":"Decreased number of striatal cholinergic interneurons and motor deficits in dopamine receptor 2-expressing-cell-specific Dyt1 conditional knockout mice.","date":"2019","source":"Neurobiology of disease","url":"https://pubmed.ncbi.nlm.nih.gov/31618684","citation_count":24,"is_preprint":false},{"pmid":"25451552","id":"PMC_25451552","title":"Decreased dopamine receptor 1 activity and impaired motor-skill transfer in Dyt1 ΔGAG heterozygous knock-in mice.","date":"2014","source":"Behavioural brain research","url":"https://pubmed.ncbi.nlm.nih.gov/25451552","citation_count":23,"is_preprint":false},{"pmid":"22022556","id":"PMC_22022556","title":"Dtorsin, the Drosophila ortholog of the early-onset dystonia TOR1A (DYT1), plays a novel role in dopamine metabolism.","date":"2011","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/22022556","citation_count":23,"is_preprint":false},{"pmid":"26297380","id":"PMC_26297380","title":"Phenotype of non-c.907_909delGAG mutations in TOR1A: DYT1 dystonia revisited.","date":"2015","source":"Parkinsonism & related disorders","url":"https://pubmed.ncbi.nlm.nih.gov/26297380","citation_count":22,"is_preprint":false},{"pmid":"12360559","id":"PMC_12360559","title":"Phenotypic variability of DYT1-PTD: does the clinical spectrum include psychogenic dystonia?","date":"2002","source":"Movement disorders : official journal of the Movement Disorder Society","url":"https://pubmed.ncbi.nlm.nih.gov/12360559","citation_count":22,"is_preprint":false},{"pmid":"32516804","id":"PMC_32516804","title":"Excess Lipin enzyme activity contributes to TOR1A recessive disease and DYT-TOR1A dystonia.","date":"2020","source":"Brain : a journal of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/32516804","citation_count":21,"is_preprint":false},{"pmid":"28627117","id":"PMC_28627117","title":"The cognitive features of idiopathic and DYT1 dystonia.","date":"2017","source":"Movement disorders : official journal of the Movement Disorder Society","url":"https://pubmed.ncbi.nlm.nih.gov/28627117","citation_count":21,"is_preprint":false},{"pmid":"25799505","id":"PMC_25799505","title":"Behavioral and electrophysiological characterization of Dyt1 heterozygous knockout mice.","date":"2015","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/25799505","citation_count":21,"is_preprint":false},{"pmid":"29150865","id":"PMC_29150865","title":"Enhanced mu opioid receptor-dependent opioidergic modulation of striatal cholinergic transmission in DYT1 dystonia.","date":"2017","source":"Movement disorders : official journal of the Movement Disorder Society","url":"https://pubmed.ncbi.nlm.nih.gov/29150865","citation_count":21,"is_preprint":false},{"pmid":"16773641","id":"PMC_16773641","title":"Non-DYT1 early-onset primary torsion dystonia: comparison with DYT1 phenotype and review of the literature.","date":"2006","source":"Movement disorders : official journal of the Movement Disorder Society","url":"https://pubmed.ncbi.nlm.nih.gov/16773641","citation_count":20,"is_preprint":false},{"pmid":"16198613","id":"PMC_16198613","title":"DYT1 mutation in a cohort of Taiwanese primary dystonias.","date":"2005","source":"Parkinsonism & related disorders","url":"https://pubmed.ncbi.nlm.nih.gov/16198613","citation_count":20,"is_preprint":false},{"pmid":"16287542","id":"PMC_16287542","title":"IL6, IL10 and TGFB1 gene polymorphisms in coeliac disease: differences between DQ2 positive and negative patients.","date":"2005","source":"Allergologia et immunopathologia","url":"https://pubmed.ncbi.nlm.nih.gov/16287542","citation_count":20,"is_preprint":false},{"pmid":"33753289","id":"PMC_33753289","title":"The evolution of dystonia-like movements in TOR1A rats after transient nerve injury is accompanied by dopaminergic dysregulation and abnormal oscillatory activity of a central motor network.","date":"2021","source":"Neurobiology of disease","url":"https://pubmed.ncbi.nlm.nih.gov/33753289","citation_count":20,"is_preprint":false},{"pmid":"24930953","id":"PMC_24930953","title":"Biochemical and cellular analysis of human variants of the DYT1 dystonia protein, TorsinA/TOR1A.","date":"2014","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/24930953","citation_count":19,"is_preprint":false},{"pmid":"20113340","id":"PMC_20113340","title":"Clinical feature and DYT1 mutation screening in primary dystonia patients from South-West China.","date":"2010","source":"European journal of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/20113340","citation_count":19,"is_preprint":false},{"pmid":"8096094","id":"PMC_8096094","title":"HLA-DQA1, DQB1 and DPB1 alleles on HLA-DQ2- and DQ9-carrying extended haplotypes.","date":"1993","source":"Tissue antigens","url":"https://pubmed.ncbi.nlm.nih.gov/8096094","citation_count":19,"is_preprint":false},{"pmid":"32976982","id":"PMC_32976982","title":"The abnormal firing of Purkinje cells in the knockin mouse model of DYT1 dystonia.","date":"2020","source":"Brain research bulletin","url":"https://pubmed.ncbi.nlm.nih.gov/32976982","citation_count":19,"is_preprint":false},{"pmid":"24862462","id":"PMC_24862462","title":"Combined occurrence of a novel TOR1A and a THAP1 mutation in primary dystonia.","date":"2014","source":"Movement disorders : official journal of the Movement Disorder Society","url":"https://pubmed.ncbi.nlm.nih.gov/24862462","citation_count":18,"is_preprint":false},{"pmid":"19028553","id":"PMC_19028553","title":"Characterization of the porcine TOR1A gene: The first step towards generation of a pig model for dystonia.","date":"2008","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/19028553","citation_count":18,"is_preprint":false},{"pmid":"18571468","id":"PMC_18571468","title":"Impaired body movement representation in DYT1 mutation carriers.","date":"2008","source":"Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology","url":"https://pubmed.ncbi.nlm.nih.gov/18571468","citation_count":18,"is_preprint":false},{"pmid":"25860259","id":"PMC_25860259","title":"Dopamine receptor and Gα(olf) expression in DYT1 dystonia mouse models during postnatal development.","date":"2015","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/25860259","citation_count":17,"is_preprint":false},{"pmid":"21800139","id":"PMC_21800139","title":"THAP1/DYT6 sequence variants in non-DYT1 early-onset primary dystonia in China and their effects on RNA expression.","date":"2011","source":"Journal of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/21800139","citation_count":17,"is_preprint":false},{"pmid":"20298201","id":"PMC_20298201","title":"TorsinA and DYT1 dystonia: a synaptopathy?","date":"2010","source":"Biochemical Society transactions","url":"https://pubmed.ncbi.nlm.nih.gov/20298201","citation_count":16,"is_preprint":false},{"pmid":"27911022","id":"PMC_27911022","title":"Membrane defects and genetic redundancy: Are we at a turning point for DYT1 dystonia?","date":"2016","source":"Movement disorders : official journal of the Movement Disorder Society","url":"https://pubmed.ncbi.nlm.nih.gov/27911022","citation_count":16,"is_preprint":false},{"pmid":"14534912","id":"PMC_14534912","title":"Developments in the molecular biology of DYT1 dystonia.","date":"2003","source":"Movement disorders : official journal of the Movement Disorder Society","url":"https://pubmed.ncbi.nlm.nih.gov/14534912","citation_count":16,"is_preprint":false},{"pmid":"26596547","id":"PMC_26596547","title":"Genetic mutations strengthen functional association of LAP1 with DYT1 dystonia and muscular dystrophy.","date":"2015","source":"Mutation research. Reviews in mutation research","url":"https://pubmed.ncbi.nlm.nih.gov/26596547","citation_count":15,"is_preprint":false},{"pmid":"35314320","id":"PMC_35314320","title":"Blockade of M4 muscarinic receptors on striatal cholinergic interneurons normalizes striatal dopamine release in a mouse model of TOR1A dystonia.","date":"2022","source":"Neurobiology of disease","url":"https://pubmed.ncbi.nlm.nih.gov/35314320","citation_count":15,"is_preprint":false},{"pmid":"27769743","id":"PMC_27769743","title":"Sensorimotor tests unmask a phenotype in the DYT1 knock-in mouse model of dystonia.","date":"2016","source":"Behavioural brain research","url":"https://pubmed.ncbi.nlm.nih.gov/27769743","citation_count":15,"is_preprint":false},{"pmid":"25447231","id":"PMC_25447231","title":"18FDG-microPET and MR DTI findings in Tor1a+/- heterozygous knock-out mice.","date":"2014","source":"Neurobiology of disease","url":"https://pubmed.ncbi.nlm.nih.gov/25447231","citation_count":14,"is_preprint":false},{"pmid":"32202496","id":"PMC_32202496","title":"TorsinB overexpression prevents abnormal twisting in DYT1 dystonia mouse models.","date":"2020","source":"eLife","url":"https://pubmed.ncbi.nlm.nih.gov/32202496","citation_count":14,"is_preprint":false},{"pmid":"36757831","id":"PMC_36757831","title":"The clinical and genetic spectrum of autosomal-recessive TOR1A-related disorders.","date":"2023","source":"Brain : a journal of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/36757831","citation_count":13,"is_preprint":false},{"pmid":"35065967","id":"PMC_35065967","title":"Structural basis of T cell receptor specificity and cross-reactivity of two HLA-DQ2.5-restricted gluten epitopes in celiac disease.","date":"2022","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/35065967","citation_count":13,"is_preprint":false},{"pmid":"20053375","id":"PMC_20053375","title":"Expression profiling in peripheral blood reveals signature for penetrance in DYT1 dystonia.","date":"2010","source":"Neurobiology of disease","url":"https://pubmed.ncbi.nlm.nih.gov/20053375","citation_count":13,"is_preprint":false},{"pmid":"34173686","id":"PMC_34173686","title":"Vesicular Acetylcholine Transporter Alters Cholinergic Tone and Synaptic Plasticity in DYT1 Dystonia.","date":"2021","source":"Movement disorders : official journal of the Movement Disorder Society","url":"https://pubmed.ncbi.nlm.nih.gov/34173686","citation_count":13,"is_preprint":false},{"pmid":"33894367","id":"PMC_33894367","title":"Cell-intrinsic effects of TorsinA(ΔE) disrupt dopamine release in a mouse model of TOR1A dystonia.","date":"2021","source":"Neurobiology of disease","url":"https://pubmed.ncbi.nlm.nih.gov/33894367","citation_count":12,"is_preprint":false},{"pmid":"29868845","id":"PMC_29868845","title":"Excess LINC complexes impair brain morphogenesis in a mouse model of recessive TOR1A disease.","date":"2018","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/29868845","citation_count":12,"is_preprint":false},{"pmid":"31583275","id":"PMC_31583275","title":"Epidemiology of DYT1 dystonia: Estimating prevalence via genetic ascertainment.","date":"2019","source":"Neurology. Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/31583275","citation_count":12,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":51265,"output_tokens":7631,"usd":0.13413,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":17238,"output_tokens":5908,"usd":0.116945,"stage2_stop_reason":"end_turn"},"total_usd":0.251075,"stage1_batch_id":"msgbatch_017qqVz33Ga63SCDwzb35XPb","stage2_batch_id":"msgbatch_01Scr2Ei9x4HJMiRGxwrmvLK","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1999,\n      \"finding\": \"TOR1A (torsinA) and its homologue TOR1B are located adjacent on chromosome 9q34, each comprising five similar exons spanning ~10 kb. The encoded proteins share functional domains with the AAA/HSP/Clp-ATPase superfamily of chaperone-like proteins, representing a distinct evolutionary branch. A family of at least nine related genes exists across human, mouse, rat, pig, zebrafish, fruitfly, and nematode.\",\n      \"method\": \"Genomic cloning, sequence analysis, database search, and phylogenetic comparison\",\n      \"journal\": \"Genomics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct genomic characterization with sequence and domain analysis, single lab but multiple orthogonal methods\",\n      \"pmids\": [\"10644435\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Mutant torsinA (ΔE) interferes with protein processing through the secretory/ER pathway. Primary fibroblasts from DYT1 patients secreted markedly less Gaussia luciferase reporter activity compared with controls, and mouse embryonic fibroblasts lacking torsinA also showed reduced secretion, supporting a role for torsinA as an ER chaperone. TorsinA was found to associate (co-fractionate) with Gluc reporter in the ER lumen.\",\n      \"method\": \"Gaussia luciferase secretion reporter assay in primary DYT1 patient fibroblasts and torsinA-null MEFs; brefeldin A/nocodazole inhibition; subcellular fractionation; fluorescent protein fusion colocalization\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (reporter assay, pharmacological inhibition, KO MEFs, fractionation), patient cells and KO cells converge on same conclusion\",\n      \"pmids\": [\"17428918\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"THAP1 (DYT6 protein), a transcription factor, directly binds the core promoter of TOR1A and represses TOR1A expression. Dystonia-6-associated mutant THAP1 shows decreased repression of TOR1A, indicating transcriptional dysregulation of TOR1A as a disease mechanism.\",\n      \"method\": \"TOR1A promoter characterization; THAP1 binding to TOR1A promoter demonstrated by reporter assay and ChIP-type analysis; luciferase reporter assay comparing wild-type vs. mutant THAP1\",\n      \"journal\": \"Annals of neurology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — promoter binding and transcriptional repression shown by multiple functional assays (promoter characterization, reporter assay, mutant comparison), single lab\",\n      \"pmids\": [\"20976771\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"The DYT1 ΔE mutation causes mutant torsinA to redistribute from the endoplasmic reticulum to the nuclear envelope. The mutation also triggers formation of abnormal intermolecular disulfide bond-dependent oligomers in torsinA. Wild-type torsinA is degraded primarily through autophagy, while the mutant form additionally requires the proteasome for efficient clearance; disulfide-linked oligomers of mutant torsinA interfere with proteasomal degradation, relying instead on autophagy.\",\n      \"method\": \"Subcellular localization studies; biochemical analysis of disulfide bonds; pharmacological inhibition of autophagy (rapamycin) and proteasome; pulse-chase degradation assays in transfected cells\",\n      \"journal\": \"Neuroscience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple biochemical methods in single lab; cell-based with pharmacological validation\",\n      \"pmids\": [\"18940237\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"The DYT1 disease-causing ΔE mutation promotes an abnormal association between torsinA and SUN1, a LINC complex component at the inner nuclear membrane. siRNA depletion of SUN1 (but not other LINC complex proteins) removes torsinA-ΔE from the nuclear envelope. This SUN1-dependent localization requires the torsinA membrane association domain and residue Y147. In contrast, ATP-locked torsinA accumulates at the NE via LAP1, not SUN1, indicating two distinct NE-localized binding interactions.\",\n      \"method\": \"Co-immunoprecipitation; siRNA knockdown of LINC complex components; subcellular localization by immunofluorescence; site-directed mutagenesis of torsinA\",\n      \"journal\": \"BMC cell biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal localization/co-IP approach, siRNA knockdown, mutagenesis; single lab\",\n      \"pmids\": [\"21627841\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Conditional knockout of Dyt1 specifically in Purkinje cells recapitulates the dendritic morphology defects (shortened primary dendrites, decreased distal dendritic spines) seen in Dyt1 ΔGAG knock-in mice, demonstrating that the torsinA effect on Purkinje cell morphology is cell-autonomous.\",\n      \"method\": \"Purkinje cell-specific Cre-mediated conditional knockout; Golgi staining for dendritic morphology quantification; comparison with ΔGAG knock-in mice\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — cell-type-specific KO with defined morphological phenotype, single lab with two complementary mouse models\",\n      \"pmids\": [\"21479250\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Loss of torsinA specifically in the striatum (striatum-specific Dyt1 conditional knockout) is sufficient to produce motor deficits and reduced striatal dopamine receptor 2 (D2R) binding activity, without significant alteration of striatal monoamine contents or nuclear envelope abnormalities in adult neurons.\",\n      \"method\": \"Striatum-specific Cre-mediated conditional knockout; behavioral motor testing; D2R radioligand binding assay; monoamine HPLC; nuclear envelope electron microscopy\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — cell-type-specific KO with defined behavioral and biochemical phenotypes, single lab\",\n      \"pmids\": [\"21931745\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Loss-of-function of Drosophila dtorsin (the sole TOR1A ortholog) results in severely reduced dopamine levels in larval and adult brains. dtorsin mutants show a strong genetic interaction with Punch (GTP cyclohydrolase/DYT14 ortholog), and biochemical analysis revealed severe reduction in GTP cyclohydrolase protein and activity, establishing that dtorsin acts as a positive regulator of GTP cyclohydrolase and dopamine biosynthesis.\",\n      \"method\": \"Drosophila null mutant generation; dopamine HPLC measurement; GTP cyclohydrolase activity assay; genetic interaction by double mutant analysis; locomotion rescue by dopamine feeding\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — ortholog null mutant, in vitro enzymatic assay, genetic epistasis, biochemical rescue; multiple orthogonal methods in single study\",\n      \"pmids\": [\"22022556\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"The D216H coding-sequence polymorphism in TOR1A moderates the effects of the DYT1 GAG deletion in cellular models and modifies clinical penetrance. In GAG-deletion carriers, the H allele in trans is highly protective against dystonia manifestation, while the D216 allele in cis with the GAG deletion is associated with disease penetrance.\",\n      \"method\": \"Population genetic analysis of DYT1 GAG-deletion carriers with/without dystonia; haplotype analysis of three TOR1A SNPs including D216H; cellular models previously established\",\n      \"journal\": \"American journal of human genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic epistasis in human cohort combined with reference to cellular model data; large cohort but primarily genetic rather than direct biochemical\",\n      \"pmids\": [\"17503336\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Novel TOR1A missense mutation p.Arg288Gln causes enlarged perinuclear space in HEK293 cells overexpressing the mutant protein, similar to the common ΔGAG mutation, supporting that Arg288 in subdomain alpha5 is functionally important for torsinA activity at the nuclear envelope.\",\n      \"method\": \"Overexpression of mutant TOR1A p.Arg288Gln in HEK293 cells; subcellular localization and nuclear envelope morphology by fluorescence/electron microscopy\",\n      \"journal\": \"Journal of neurology, neurosurgery, and psychiatry\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single overexpression experiment, single lab, morphological readout only\",\n      \"pmids\": [\"18477710\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"A novel TOR1A missense mutation F205I (in the AAA-ATPase domain) produces frequent intracellular inclusions when expressed in cells, similar to the ΔGAG mutation, providing functional evidence that this mutation impairs torsinA function.\",\n      \"method\": \"Expression assay with F205I and ΔGAG TOR1A variants; intracellular inclusion formation scored by microscopy\",\n      \"journal\": \"Journal of medical genetics\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single overexpression/inclusion assay, single lab, no biochemical mechanism established\",\n      \"pmids\": [\"19955557\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Rare TOR1A variants R288Q and F205I share biochemical and cellular properties with pathogenic torsinAΔE (altered oligomerization, subcellular redistribution toward nuclear envelope, altered degradation via autophagy-lysosome pathway), whereas wild-type torsinA does not display these features. Autophagy-lysosome pathway is the preferred degradation route for both wild-type and most mutant torsinA forms.\",\n      \"method\": \"Subcellular localization assays; co-immunoprecipitation for oligomerization; autophagy/proteasome pharmacological inhibition; protein stability assays; comparison across multiple variants\",\n      \"journal\": \"Human mutation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal biochemical assays across variants in single lab\",\n      \"pmids\": [\"24930953\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"TOR1A mutant variants (including ΔGAG) show preferred degradation through the autophagy-lysosome pathway. Blocking autophagy with bafilomycin significantly increases inclusion formation for the E121K variant. The p.A14_P15del mutation affects the proposed oligomerization domain but does not abolish dimerization.\",\n      \"method\": \"Autophagy inhibition (bafilomycin), protein stability assays, co-immunoprecipitation for dimerization, inclusion body scoring in transfected cells\",\n      \"journal\": \"Human mutation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple biochemical methods, single lab\",\n      \"pmids\": [\"24931141\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Gene dosage studies using a conditional knock-in allele demonstrate that ΔE-torsinA is a hypomorphic (loss-of-function) allele with no evidence for gain-of-function toxic properties. The ΔE mutation does not produce dominant negative or toxic gain-of-function effects at the molecular or organismal level.\",\n      \"method\": \"Conditional Tor1a knock-in allele converted by Cre recombinase; gene dosage study comparing homozygous, heterozygous and wild-type animals at molecular, neuropathological, and behavioral levels\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — conditional allele with systematic dosage study, multiple phenotypic levels assessed, single lab\",\n      \"pmids\": [\"26370418\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"D2 receptor protein is reduced in the striatum of juvenile Dyt1 mice through increased lysosomal degradation, controlled by competition between β-arrestin 2 and D2 receptor binding proteins. Striatal RGS9-2 and spinophilin levels are lower in Dyt1 mice. RGS9-2 overexpression rescues both D2 receptor levels and electrophysiological responses in Dyt1 striatal neurons, while RGS9-2 knockout mimics the D2 receptor loss phenotype.\",\n      \"method\": \"Radioligand binding; Western blot; genetic RGS9-2 knockout and overexpression (viral); electrophysiology in striatal neurons; lysosomal pathway inhibition\",\n      \"journal\": \"EMBO molecular medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal genetic loss and gain of function with defined biochemical and electrophysiological readouts, mechanistic pathway established, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"30552094\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Lipin phosphatidic acid phosphatase (PAP) enzyme activity is abnormally elevated in human DYT-TOR1A patient iPSC-derived neurons and in four different Tor1a mouse model brains, correlating with Tor1a mutation dosage. Genetic reduction of Lpin1 improves survival of recessive Tor1a disease mice and suppresses neurodegeneration, motor dysfunction, and nuclear membrane pathology, establishing that torsinA loss causes abnormal phosphatidic acid metabolism through excess Lipin activity.\",\n      \"method\": \"Lipin PAP enzyme activity assay in patient iPSC-derived neurons and mouse brains; genetic interbreeding of Tor1a and Lpin1 knockout mice; behavioral, histopathological, and nuclear membrane analysis\",\n      \"journal\": \"Brain : a journal of neurology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — enzymatic activity assay in human patient cells, multiple mouse models, genetic rescue by Lpin1 KO cross; multiple orthogonal methods across labs\",\n      \"pmids\": [\"32516804\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"TorsinB levels bidirectionally regulate DYT1 disease phenotypes. Reducing torsinB levels worsens abnormal movements and neuropathology in DYT1 mouse models in a dose-dependent manner, while torsinB overexpression rescues torsinA loss-of-function-mediated abnormal movements and neurodegeneration, identifying torsinB as a functional paralog capable of compensating for torsinA loss.\",\n      \"method\": \"Genetic reduction and overexpression of torsinB in DYT1 mouse models; behavioral testing; neuropathological analysis\",\n      \"journal\": \"eLife\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — bidirectional genetic manipulation (KO and OE) with defined behavioral and neuropathological readouts in validated disease model\",\n      \"pmids\": [\"32202496\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Human DYT1 patient-specific motor neurons (from iPSCs or direct conversion) show LMNB1 upregulation and abnormal subcellular distribution specifically in cholinergic motor neurons. Ectopic expression of mutant TOR1A or shRNA knockdown of TOR1A in healthy control motor neurons recapitulates LMNB1 dysregulation. Downregulation of LMNB1 ameliorates all major cellular defects in DYT1 motor neurons (reduced neurite length/branching, thickened nuclear lamina, disrupted nuclear morphology, impaired nucleocytoplasmic transport).\",\n      \"method\": \"iPSC differentiation and direct conversion to cholinergic motor neurons from DYT1 patients; shRNA knockdown; mutant TOR1A overexpression; neurite morphometry; nuclear lamina thickness measurement; nucleocytoplasmic transport assays; Western blot\",\n      \"journal\": \"The Journal of neuroscience : the official journal of the Society for Neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — human patient-specific neurons, reciprocal gain/loss of function, multiple orthogonal readouts, mechanism-to-rescue validation\",\n      \"pmids\": [\"33468570\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"In the Tor1a+/Δgag DYT1 mouse model, long-term potentiation (LTP) appears prematurely in a critical developmental window in striatal spiny neurons while LTD is absent. This is accompanied by increased dendritic spine width, mature mushroom spines, and enhanced AMPA receptor accumulation. BDNF and proBDNF levels are elevated in Tor1a+/Δgag mice, and BDNF antagonism rescues both synaptic plasticity deficits and AMPA currents.\",\n      \"method\": \"Electrophysiological recording (LTP/LTD) in striatal spiny neurons; dendritic spine morphometry; Western blot for AMPAR and BDNF; pharmacological BDNF antagonism\",\n      \"journal\": \"eLife\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — electrophysiology combined with morphological, biochemical, and pharmacological rescue; multiple methods in single study\",\n      \"pmids\": [\"29504938\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Increased vesicular acetylcholine transporter (VAChT) protein levels in the striatum of Tor1a+/- mice lead to elevated basal acetylcholine content and compensatory enhancement of acetylcholinesterase (AChE) activity. Dopamine D2 receptor activation abnormally elevates ACh content (rather than reducing it). Pharmacological blockade of VAChT with vesamicol rescues corticostriatal long-term synaptic plasticity deficits in DYT1 mice.\",\n      \"method\": \"Western blot for VAChT; acetylcholine content assay; AChE enzymatic activity assay; patch-clamp electrophysiology; pharmacological VAChT inhibition (vesamicol)\",\n      \"journal\": \"Movement disorders : official journal of the Movement Disorder Society\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — enzymatic activity assay, biochemical quantification, electrophysiology with pharmacological rescue; multiple orthogonal methods, single lab\",\n      \"pmids\": [\"34173686\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Conditional expression of Tor1a(ΔE) in dopamine neurons (but not in cholinergic interneurons) reduces striatal dopamine release to ~50% of normal, demonstrating that the dopamine release deficit in DYT1 dystonia is cell-intrinsic to dopaminergic neurons. Other presynaptic mechanisms (electrical excitability, vesicle recycling, Ca2+ signaling, D2 autoreceptor function, GABAB receptor function) are intact in these neurons.\",\n      \"method\": \"Cell-type-specific conditional expression of Tor1a(ΔE) via Cre drivers; ex vivo fast-scan cyclic voltammetry; in vivo microdialysis; multiple presynaptic mechanism assays\",\n      \"journal\": \"Neurobiology of disease\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — cell-type-specific conditional expression with multiple orthogonal electrophysiological and neurochemical assays to define mechanism\",\n      \"pmids\": [\"33894367\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"M4 muscarinic receptors on striatal cholinergic interneurons mediate the dopamine-release-enhancing and therapeutic effects of trihexyphenidyl in Tor1a+/ΔE knockin mice. Selective M4 antagonist VU6021625 recapitulates the effect of trihexyphenidyl in restoring striatal dopamine release.\",\n      \"method\": \"Pharmacological challenges with selective mAChR antagonists; cell-type-specific M4 conditional knockout mice; ex vivo fast-scan cyclic voltammetry\",\n      \"journal\": \"Neurobiology of disease\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — cell-type-specific KO combined with pharmacology and voltammetry; mechanistic pathway from mAChR to dopamine release established\",\n      \"pmids\": [\"35314320\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Conditional knockout of Tor1a in the spinal cord and dorsal root ganglia (but not DRG alone) recapitulates early-onset generalized torsion dystonia in mice. Physiological features include spontaneous contractions at rest, excessive/disorganized contractions, co-contractions of antagonist muscles, impaired monosynaptic reflexes, and affected motor neurons in isolated spinal cords, establishing spinal neural circuits as the pathophysiological substrate in this model.\",\n      \"method\": \"Spinal cord-specific and DRG-specific conditional knockout; behavioral scoring; EMG; electrophysiological recording from isolated spinal cords; monosynaptic reflex arc analysis\",\n      \"journal\": \"Science translational medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — cell-type-specific KO with defined behavioral, EMG, and electrophysiological phenotypes; DRG-only KO as negative control strengthens specificity\",\n      \"pmids\": [\"37134150\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Loss of torsinA in the nuclear envelope disrupts LINC complex regulation, causing excess LINC complex accumulation in radial glial cells of Tor1a-/- mouse embryo proliferative zones. This leads to abnormal radial glial polarity and cytoskeletal organization and brain morphogenesis defects in ~30% of Tor1a-/- embryos. Genetic reduction of LINC complexes prevents abnormal brain morphogenesis.\",\n      \"method\": \"Tor1a-/- embryo brain morphology analysis; immunohistochemistry for LINC complex components and radial glial markers; genetic rescue by LINC complex reduction\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic KO with LINC complex quantification and genetic rescue, single lab\",\n      \"pmids\": [\"29868845\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Trihexyphenidyl increases striatal dopamine release through nicotinic acetylcholine receptor (nAChR)-dependent mechanisms. Dyt1 mice are more sensitive to nAChR antagonism (IC50 ~12 nM vs. ~29 nM in WT) and less sensitive to acetylcholinesterase inhibitors, indicating altered nAChR neurotransmission in DYT1 mice. L-DOPA does not increase dopamine release in Dyt1 mice.\",\n      \"method\": \"Ex vivo fast-scan cyclic voltammetry; in vivo microdialysis; pharmacological dissection with nAChR antagonists, AChE inhibitors, and L-DOPA\",\n      \"journal\": \"Neurobiology of disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple pharmacological tools and two complementary neurochemical methods; single lab\",\n      \"pmids\": [\"30707939\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Loss of torsinA function in the cerebral cortex alone (cerebral cortex-specific Dyt1 conditional knockout) is sufficient to produce motor deficits and hyperactivity. Cortex-specific KO mice did not show significant alterations in striatal dopamine and metabolites, unlike Dyt1 ΔGAG knock-in mice.\",\n      \"method\": \"Cerebral cortex-specific Cre-mediated conditional knockout; behavioral testing (open field, rotarod); monoamine HPLC; barrel cortex anatomy\",\n      \"journal\": \"Journal of biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — cell-type-specific KO with behavioral and neurochemical phenotyping; single lab\",\n      \"pmids\": [\"17956903\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Torsin A loss in D2 receptor-expressing cells (including striatal cholinergic interneurons) leads to significant reductions in: striatal torsinA, acetylcholine metabolic enzymes, TrkA, cholinergic interneuron number, D2R dimers, and tyrosine hydroxylase. This demonstrates that torsinA in D2R-expressing cells is critical for the development/survival of striatal cholinergic interneurons and expression of mature D2R.\",\n      \"method\": \"D2R-expressing-cell-specific Cre conditional knockout; stereological counting of cholinergic interneurons; Western blot; rotarod and beam-walking tests; monoamine HPLC\",\n      \"journal\": \"Neurobiology of disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — cell-type-specific KO with multiple biochemical and histological endpoints; single lab\",\n      \"pmids\": [\"31618684\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Novel TOR1A mutation p.Asp194Val (in a patient with early-onset segmental dystonia) induces intracellular inclusion formation in SK-N-AS cells, similar to ΔGAG TOR1A. Co-occurrence with a THAP1 mutation (Leu180Ser) with decreased THAP1 repression of TOR1A suggests a potential additive pathogenic effect.\",\n      \"method\": \"TOR1A overexpression in SK-N-AS cells; inclusion body scoring; luciferase reporter assay for THAP1 repression of TOR1A promoter\",\n      \"journal\": \"Movement disorders : official journal of the Movement Disorder Society\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single overexpression assay and luciferase reporter, single patient/lab\",\n      \"pmids\": [\"24862462\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"TOR1A variants p.Gly318Ser and p.Glu303del (homozygous) cause redistribution of torsinA from the ER to the nuclear envelope in cell assays, establishing this NE redistribution as a common cellular hallmark of pathogenic TOR1A mutations and linking biallelic mutations to a severe arthrogryposis phenotype.\",\n      \"method\": \"Cell-based torsinA subcellular localization assay (overexpression); comparison of WT vs. mutant localization\",\n      \"journal\": \"Brain : a journal of neurology\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single localization assay, single lab\",\n      \"pmids\": [\"29053766\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"TorsinA is an AAA+-family chaperone-like ATPase that normally resides in the ER lumen and nuclear envelope, where it regulates nuclear envelope integrity (via LAP1 and SUN1/LINC complex interactions), protein secretion through the ER, phosphatidic acid metabolism (via Lipin regulation), and dopamine neurotransmission (cell-intrinsically within dopaminergic neurons via an unknown presynaptic mechanism); the disease-causing ΔE mutation renders it hypomorphic, redistributes it to the nuclear envelope via an aberrant SUN1 interaction, elevates LMNB1 in neurons, disrupts nucleocytoplasmic transport, impairs corticostriatal synaptic plasticity through excess VAChT/acetylcholine and altered BDNF-AMPAR signaling, reduces striatal D2R levels through increased lysosomal degradation controlled by RGS9-2/β-arrestin competition, and can be functionally compensated by its paralog torsinB.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"TorsinA, encoded by TOR1A, is an AAA+/HSP/Clp-superfamily chaperone-like ATPase that resides in the ER lumen and contiguous nuclear envelope and supports nuclear envelope integrity, ER protein secretion, lipid metabolism, and dopaminergic neurotransmission [#0, #1]. In the ER it acts as a chaperone facilitating protein processing through the secretory pathway, as DYT1 patient fibroblasts and torsinA-null cells secrete a reporter poorly [#1]. At the nuclear envelope torsinA regulates the LINC complex: its loss causes excess LINC accumulation that disrupts radial glial polarity, cytoskeletal organization, and brain morphogenesis, all preventable by genetically reducing LINC complexes [#23], and ATP-locked torsinA accumulates at the nuclear envelope via LAP1 [#4]. TorsinA loss also drives abnormal phosphatidic acid metabolism through excess Lipin phosphatidic acid phosphatase activity, and reducing Lpin1 rescues neurodegeneration, motor dysfunction, and nuclear membrane pathology in disease mice [#15]. The dystonia-causing in-frame GAG (\\u0394E) deletion is a hypomorphic loss-of-function allele rather than a toxic gain-of-function [#13]; mutant torsinA forms aberrant disulfide-linked oligomers, redistributes from the ER to the nuclear envelope via an abnormal SUN1 interaction, and is cleared preferentially through the autophagy-lysosome pathway [#3, #4, #11]. This redistribution and altered degradation is a shared cellular hallmark of pathogenic TOR1A variants [#11, #28]. The functional paralog torsinB compensates bidirectionally for torsinA loss [#16], and TOR1A expression is transcriptionally repressed by the dystonia-6 protein THAP1 [#2]. Downstream, torsinA dysfunction within dopaminergic neurons cell-intrinsically reduces striatal dopamine release [#20], lowers striatal D2 receptor levels via increased lysosomal degradation governed by RGS9-2/\\u03b2-arrestin competition [#14], and disrupts corticostriatal synaptic plasticity through excess VAChT/acetylcholine and altered BDNF\\u2013AMPAR signaling [#18, #19]; in human patient motor neurons, mutant torsinA upregulates LMNB1 and impairs nucleocytoplasmic transport, with LMNB1 reduction reversing these defects [#17]. Conditional knockouts establish that spinal/DRG circuits are a pathophysiological substrate for the dystonia phenotype [#22]. TOR1A mutations cause early-onset torsion dystonia (DYT1) and, biallelically, a severe arthrogryposis phenotype [#28].\",\n  \"teleology\": [\n    {\n      \"year\": 1999,\n      \"claim\": \"Establishing TOR1A as an AAA+/HSP/Clp-family chaperone-like ATPase defined the molecular class through which all downstream functions could be interpreted.\",\n      \"evidence\": \"Genomic cloning, sequence and domain analysis, and phylogenetic comparison across species\",\n      \"pmids\": [\"10644435\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No direct ATPase activity or substrate demonstrated\", \"Subcellular localization not yet established\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Demonstrating impaired secretion in patient and null cells assigned torsinA a concrete ER chaperone role in the secretory pathway.\",\n      \"evidence\": \"Gaussia luciferase secretion reporter in DYT1 fibroblasts and torsinA-null MEFs with pharmacological inhibition and fractionation\",\n      \"pmids\": [\"17428918\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Specific secretory client substrates not identified\", \"Link between secretion defect and neuronal phenotype unresolved\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Identification of the D216H polymorphism as a penetrance modifier showed that torsinA dosage/activity, not the mutation alone, governs disease manifestation.\",\n      \"evidence\": \"Population genetics and haplotype analysis of GAG-deletion carriers with cellular model reference\",\n      \"pmids\": [\"17503336\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Biochemical basis of D216H protection not fully defined\", \"Cell-type context of modifier effect unknown\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Showing that the \\u0394E mutation redistributes torsinA to the nuclear envelope and shifts its degradation defined the core cellular pathology of mutant protein.\",\n      \"evidence\": \"Subcellular localization, disulfide-bond biochemistry, and pharmacological autophagy/proteasome inhibition with pulse-chase in transfected cells\",\n      \"pmids\": [\"18940237\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Functional consequence of NE redistribution not established here\", \"Driver of NE retention unknown at this stage\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Identifying THAP1 as a direct transcriptional repressor of TOR1A connected two genetic dystonia loci into a shared regulatory pathway.\",\n      \"evidence\": \"Promoter characterization, ChIP-type binding, and reporter assays comparing wild-type vs mutant THAP1\",\n      \"pmids\": [\"20976771\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo relevance of TOR1A transcriptional dysregulation to dystonia not shown\", \"Other THAP1 target genes not delineated\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Defining SUN1 as the driver of mutant torsinA NE accumulation, distinct from LAP1-mediated ATP-locked accumulation, explained the abnormal localization mechanism.\",\n      \"evidence\": \"Co-immunoprecipitation, LINC-component siRNA depletion, and site-directed mutagenesis with immunofluorescence\",\n      \"pmids\": [\"21627841\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Functional consequence of aberrant SUN1 binding unresolved\", \"Single-lab interaction data\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Cell-type-specific knockouts dissected which neural populations require torsinA, mapping Purkinje cell morphology, striatal motor/D2R, and cortical motor functions to distinct circuits.\",\n      \"evidence\": \"Purkinje-, striatum-, and cortex-specific conditional Dyt1 knockouts with morphology, behavior, D2R binding, and HPLC\",\n      \"pmids\": [\"21479250\", \"21931745\", \"17956903\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Molecular mechanism linking torsinA loss to each phenotype not resolved\", \"Cross-circuit interactions not addressed\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"The Drosophila ortholog established torsinA as a positive regulator of GTP cyclohydrolase and dopamine biosynthesis, providing a biosynthetic link to dopaminergic deficits.\",\n      \"evidence\": \"dtorsin null mutants with dopamine HPLC, GTP cyclohydrolase activity assay, genetic interaction with Punch, and dopamine-feeding rescue\",\n      \"pmids\": [\"22022556\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct biochemical mechanism of GTP cyclohydrolase regulation unknown\", \"Conservation of this pathway in mammalian dopaminergic neurons not confirmed\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Comparative biochemistry of multiple rare variants established NE redistribution, altered oligomerization, and autophagy-lysosome degradation as common signatures of pathogenic torsinA.\",\n      \"evidence\": \"Subcellular localization, co-IP oligomerization, autophagy/proteasome inhibition, and stability assays across variants\",\n      \"pmids\": [\"24930953\", \"24931141\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Oligomerization domain structure unresolved\", \"Quantitative relationship between degradation route and dysfunction unclear\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Gene-dosage studies showed \\u0394E-torsinA is hypomorphic with no toxic gain-of-function, reorienting the disease model toward loss of function.\",\n      \"evidence\": \"Cre-convertible conditional knock-in allele with homozygous/heterozygous/WT comparison at molecular, neuropathological, and behavioral levels\",\n      \"pmids\": [\"26370418\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Why heterozygous loss suffices for human dystonia not explained\", \"Threshold of activity loss needed for phenotype undefined\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Linking torsinA loss to LINC complex over-accumulation defined a concrete nuclear envelope mechanism for developmental brain pathology.\",\n      \"evidence\": \"Tor1a-/- embryo morphology, LINC and radial glial immunohistochemistry, and genetic rescue by LINC complex reduction\",\n      \"pmids\": [\"29868845\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism by which torsinA limits LINC accumulation not defined\", \"Relevance to adult dystonia circuits unclear\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Identifying premature LTP, absent LTD, and BDNF-dependent AMPAR changes linked torsinA loss to a developmental synaptic plasticity defect.\",\n      \"evidence\": \"Striatal LTP/LTD electrophysiology, spine morphometry, AMPAR/BDNF Western blot, and pharmacological BDNF antagonism in Tor1a+/\\u0394gag mice\",\n      \"pmids\": [\"29504938\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism linking torsinA to BDNF elevation unknown\", \"Causal sequence between plasticity and motor signs unresolved\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Defining RGS9-2/\\u03b2-arrestin-controlled lysosomal degradation of D2R, and the cholinergic dependence of torsinA, mechanistically linked torsinA loss to striatal dopamine/acetylcholine imbalance.\",\n      \"evidence\": \"Reciprocal RGS9-2 KO/overexpression, radioligand binding, electrophysiology, lysosomal inhibition, and D2R-cell-specific conditional KO\",\n      \"pmids\": [\"30552094\", \"31618684\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How torsinA loss lowers RGS9-2/spinophilin not defined\", \"Connection between D2R reduction and motor output indirect\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Pharmacological dissection showed trihexyphenidyl restores striatal dopamine release via altered nAChR neurotransmission, framing anticholinergic therapy mechanistically.\",\n      \"evidence\": \"Fast-scan cyclic voltammetry and microdialysis with nAChR antagonists, AChE inhibitors, and L-DOPA in Dyt1 mice\",\n      \"pmids\": [\"30707939\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Molecular basis of altered nAChR sensitivity unknown\", \"L-DOPA insensitivity mechanism unexplained\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Establishing torsinB as a dose-dependent functional paralog and Lipin/phosphatidic acid metabolism as a torsinA-controlled pathway identified two distinct rescue-capable mechanisms.\",\n      \"evidence\": \"Bidirectional torsinB manipulation in DYT1 mice; Lipin PAP activity assays in patient iPSC neurons and mouse brains with Lpin1 KO genetic rescue\",\n      \"pmids\": [\"32202496\", \"32516804\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Biochemical mechanism by which torsinA restrains Lipin activity unknown\", \"How torsinB substitutes for torsinA molecularly undefined\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Human patient motor neurons localized the disease mechanism to LMNB1 upregulation and impaired nucleocytoplasmic transport, with LMNB1 reduction reversing defects.\",\n      \"evidence\": \"iPSC and direct-conversion cholinergic motor neurons, reciprocal mutant TOR1A overexpression and shRNA knockdown, morphometry, nuclear lamina measurement, and transport assays\",\n      \"pmids\": [\"33468570\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanistic link between torsinA loss and LMNB1 upregulation unresolved\", \"Cell-type specificity of LMNB1 dysregulation not fully explained\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Cell-intrinsic conditional expression studies and VAChT findings pinpointed the dopamine-release deficit to dopaminergic neurons and the plasticity deficit to excess vesicular acetylcholine.\",\n      \"evidence\": \"Cell-type-specific Tor1a(\\u0394E) expression with voltammetry/microdialysis; VAChT Western blot, ACh and AChE assays, and vesamicol rescue\",\n      \"pmids\": [\"33894367\", \"34173686\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Presynaptic molecular target of torsinA in dopamine neurons unidentified\", \"Mechanism elevating VAChT unknown\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Defining M4 muscarinic receptors on cholinergic interneurons as the mediator of anticholinergic dopamine-release enhancement refined the circuit pharmacology of therapy.\",\n      \"evidence\": \"Selective mAChR antagonists, M4 cell-type-specific conditional knockout, and fast-scan cyclic voltammetry\",\n      \"pmids\": [\"35314320\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Upstream link from torsinA loss to M4 signaling not established\", \"Generalizability to human therapy untested in this model\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Spinal cord/DRG conditional knockout identified spinal neural circuits as a sufficient pathophysiological substrate for generalized dystonia.\",\n      \"evidence\": \"Spinal- and DRG-specific conditional knockouts with behavior, EMG, isolated spinal cord recording, and monosynaptic reflex analysis\",\n      \"pmids\": [\"37134150\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular mechanism within spinal neurons undefined\", \"Integration of spinal substrate with striatal circuit findings unresolved\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How torsinA's ER/NE chaperone-ATPase activity mechanistically converges on its diverse downstream effects (LINC, Lipin, LMNB1, dopamine release, cholinergic signaling) remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No defined enzymatic substrate connecting torsinA ATPase activity to downstream phenotypes\", \"No structural model of the relevant torsinA complexes in the corpus\", \"Mechanism translating molecular dysfunction into circuit-level dystonia not unified\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140657\", \"supporting_discovery_ids\": [0]},\n      {\"term_id\": \"GO:0044183\", \"supporting_discovery_ids\": [0, 1]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [7, 15]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005783\", \"supporting_discovery_ids\": [1, 3]},\n      {\"term_id\": \"GO:0005635\", \"supporting_discovery_ids\": [3, 4, 23]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [1, 3, 11]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [13, 17, 22]},\n      {\"term_id\": \"R-HSA-112316\", \"supporting_discovery_ids\": [14, 18, 20]}\n    ],\n    \"complexes\": [\"LINC complex\"],\n    \"partners\": [\"SUN1\", \"LAP1\", \"THAP1\", \"LMNB1\", \"TOR1B\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":10,"faith_total":10,"faith_pct":100.0}}